Clinical Trials on High-Risk and Oligometastatic Prostate Cancer in United States

Total 3556 results

The Methodist Hospital Research Institute

Recruiting

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Prostate Cancer | High-risk Prostate Cancer

United States
Won Kim
Novartis

Terminated

Neoadjuvant BKM120 in High-risk Prostate Cancer

High Risk Prostate Cancer

United States
University of Florida

Completed

Radiotherapy for Oligometastatic Prostate Cancer

Oligometastatic Prostate Cancer

United States
Dana-Farber Cancer Institute
Medivation, Inc.

Completed

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Prostate Cancer | Prostate Adenocarcinoma | High Risk Prostate Cancer

United States
VA Office of Research and Development

Recruiting

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (SNARE)

High-Risk Prostate Cancer

United States
Ivan de Kouchkovsky, MD

Not yet recruiting

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) MRI as a Response Monitoring Tool to Neoadjuvant Abiraterone

Prostate Cancer | High Risk Prostate Carcinoma

United States
Prisma Health-Upstate

Recruiting

Prevent Cancer- Greenville (CCPW)

Cancer | High-Risk Cancer

United States
The Methodist Hospital Research Institute

Completed

68 Ga-PSMA for High Risk Prostate Cancer

Prostate Cancer | High Risk

United States
Rana McKay, MD
University of California, San Diego; AstraZeneca

Recruiting

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Prostatic Adenocarcinoma | High-Risk Cancer

United States
Catherine Spina
Arcus Biosciences, Inc.

Recruiting

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer (SBRT-AMICO)

Oligometastatic Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
VA Office of Research and Development

Completed

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Newly Diagnosed Oligometastatic Prostate Cancer

United States
Dana-Farber Cancer Institute
Medivation, Inc.

Completed

Enzalutamide + External Beam Rt For Prostate

Intermediate Risk Prostate Cancer

United States
RPCR, Inc.

Unknown

Multi-Institutional Registry for Prostate Cancer Radiosurgery (RPCR)

Prostate Cancer Early Risk Treated by Radiosurgery | Prostate Cancer Intermediate Risk Treated by Radiosurgery

United States
Henry Ford Health System
American Cancer Society, Inc.

Withdrawn

Phase I Study MR-guided SBRT to PCa (MRgRTPCa)

Low or Intermediate Risk Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Prostate Cancer | Oligometastatic Disease | Castrate Sensitive Prostate Cancer

United States
University of Oxford
Vaccitech (UK) Limited

Unknown

VAccination in Early and ADvanced Prostate caNCEr (ADVANCE)

Castration-resistant Prostate Cancer | Intermediate Risk Prostate Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center

Completed

A Risk Assessment Tool to Increase Statin Use Among High Risk Cancer Survivors: Development and Pilot Testing

Cancer Survivors | Statin Use Among High Risk Survivors

United States
Jonsson Comprehensive Cancer Center
POINT Biopharma

Active, not recruiting

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (LUNAR)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer (NRG PROMETHEAN)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States, Canada
Angle plc
MidLantic Urology, LLC

Terminated

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (CHARTER)

Prostate Cancer | Castration-resistant Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | High Risk Prostate Carcinoma

United States
Novartis Pharmaceuticals

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (PSMA-DC)

Oligometastatic Prostate Cancer (OMPC)

Japan, Singapore, Canada, Israel, Switzerland, Australia, United States
VA Office of Research and Development

Recruiting

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT)

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Oligometastasis | Oligorecurrence | De Novo Prostate Cancer

United States
Genesis Research LLC

Recruiting

Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging

Prostate Cancer | Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen

United States
University of Maryland, Baltimore

Recruiting

TERPS Trial for de Novo Oligometastic Prostate Cancer

Prostate Cancer | Oligometastatic Disease

United States
Mayo Clinic

Recruiting

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Biochemically Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate Adenocarcinoma

United States
Mayo Clinic

Not yet recruiting

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
University of Maryland, Baltimore
Janssen Scientific Affairs, LLC

Recruiting

High-Risk Metachronous Oligometastatic Prostate Cancer Trial (KNIGHTS)

Prostate Cancer | Oligometastatic Disease

United States
Memorial Sloan Kettering Cancer Center
Icahn School of Medicine at Mount Sinai

Active, not recruiting

Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies

Low Risk Prostate Cancer

United States
InSightec

Completed

Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study

Localized Low-Intermediate Risk Prostate Cancer

United Kingdom, Israel, Canada, Italy, Singapore
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
Mayo Clinic

Recruiting

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer

Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
National Cancer Institute (NCI)

Completed

Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk

Risk Reduction Behavior | High Risk for Breast Cancer

United States
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
Nuvation Bio Inc.

Withdrawn

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Prostate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic Neoplasms

United States
Roswell Park Cancer Institute
University of Pittsburgh

Completed

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of Prostate

United States
VA Office of Research and Development

Recruiting

A Balanced Reach Training Platform to Address Balance Disorders in Older and Neurologically Disabled Veterans (BRTP)

Older Men and Women With High Fall Risk

United States
University of Pennsylvania

Completed

Can Birthly, an Online Childbirth Education Platform, Reduce Pregnancy-related Anxiety Compared to Usual Care (Birthly)

Pregnancy, High Risk

United States
University of Washington
National Cancer Institute (NCI)

Completed

Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Prostate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Patient-Centered Outcomes Research Institute

Completed

North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)

Prostate Cancer | Cancer of the Prostate | Prostatic Cancer | Cancer of Prostate

United States
GTx
Ipsen

Withdrawn

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer (TREAT2)

Risk of Bone Fracture Occurrences

United States
Ohio State University Comprehensive Cancer Center
Riverside Methodist Hospital

Completed

Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery

Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

High-Dose Stereotactic Radiation for Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Swedish Medical Center

Recruiting

Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Prostatic Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
University of California, Irvine

Completed

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Institutes of Health (NIH)

Completed

Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery

Prostate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIB Prostate Cancer

United States
University of California, Irvine

Recruiting

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)

Pregnancy, High Risk | Anticoagulants

United States
Barbara Ann Karmanos Cancer Institute
Genentech, Inc.

Completed

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States

Clinical Trials on High-Risk and Oligometastatic Prostate Cancer in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations